Shaji Kumar, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene 
    Date added:
    09/22/2021
    Date updated:
    12/12/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates
    Date added:
    09/22/2021
    Date updated:
    12/12/2023
Return to 2023 Annual Summit on Hematologic Cancers: Incorporation of Novel Therapies in Clinical Practice